Navigation Links
Lotus Pharmaceuticals Terminates SEDA
Date:7/22/2010

, asthma and diabetes. Liang Fang sells drugs directly and indirectly through its national sales channels to hospitals, clinics and drugs stores in 30 provinces of the PRC.

Safe Harbor Statement

This press release contains "forward-looking statements" within the meaning of the "safe-harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate, or imply future results, performance or achievements, and may contain the words "estimate," "project," "intent," "forecast," "anticipate," "plan," "planning," "expect," "believe," "will likely," "should," "could," "would," "may," or words or expressions of similar meaning. Such statements are not guarantees of future performance and could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including, but not limited to, changes from anticipated levels of sales, future national or regional economic and competitive and regulatory conditions, changes in relationships with customers, access to capital, increased costs, difficulties in developing and marketing new products, marketing existing products, customer acceptance of existing and new products, the time to get new drugs approved by the State Food and Drug Administration and other factors. Additional information regarding risks can be found in the Company's Annual Report on Form 10K and its other filings with the SEC. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to update the forward-looking information contained in this press release.

    For more information, please contact:

    Lotus P
'/>"/>
SOURCE Lotus Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lotus Pharmaceuticals to Present at Global Hunter Securities 2010 China Conference
2. Pink Lotus Breast Center to Integrate Electronic Brachytherapy Cancer Treatment Platform
3. Lotus Pharmaceuticals, Inc. Reports Strong First Quarter 2010 Financial Results
4. Lotus Pharmaceuticals Laevo-Bambuterol Received SFDA Approval to Commence Clinical Trials
5. Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA
6. Lotus Pharmaceuticals Reports Groundbreaking Ceremony
7. Lotus Pharmaceuticals, Inc. Strengthens Beijing Presence with Direct Sales to Drug Stores
8. Lotus Pharmaceuticals, Inc. to Exhibit at the 62nd PHARMCHINA
9. Lotus Pharmaceuticals, Inc. Reports Third-Quarter 2009 Results
10. Lotus Pharmaceuticals, Inc.s New Drug Laevo-Bambutero Begins Evaluation for Clinical Trials
11. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... IRVING, Texas , Jan. 15, 2014  Novation, the ... company, awarded several new IT value-added reseller (VAR) national ... with IT goods and services at lower costs. These ... value-added services such as initiative assistance and ongoing IT ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... FORT WORTH, Texas , Jan. 15, 2014  Humberto ... in Dermatology Achievement Award" from the Journal of ... Dermatology Aesthetic & Clinical Conference (ODAC). The event is January ... Florida . The ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... 17 Innocoll, Inc., a privately-held,biopharmaceutical company, ... phase,2 clinical trials sponsored by its wholly ... GENTAMICIN TOPICAL for the,treatment and prevention of ... GENTAMICIN TOPICAL is a biodegradable and fully ...
... Biosciences,Incorporated (Nasdaq: KOSN ) presented preclinical data ... in vitro and in vivo,activity as well as ... NEI anticancer mechanism of action correlating inhibition,of the ... cancer cells,compared to normal cells. Data on Kosan,s ...
Cached Medicine Technology:Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 2Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 3Innocoll Announces Dosing of First Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) GENTAMICIN TOPICAL for the Treatment of Moderately Infected Diabetic Foot Ulcers 4Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 2Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 3Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR 4
(Date:4/23/2014)... research, published in the journal Oncotarget , ... different appearances or their own DNA signatures within ... difficult to design effective, targeted treatment strategies. , ... EGFR mutation and either the KRAS or BRAF ... by the EGFR gene mutation have that specific ...
(Date:4/22/2014)... is a popular high school sport in the United ... study by researchers in the Center for Injury Research ... to compare and describe the occurrence and distribution patterns ... high school athletic training setting among adolescents and teens. ... of Athletic Training , examined data relating to adolescents ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... 2014: The Association for Molecular Pathology (AMP) released ... Molecular Diagnostics on recommendations for a molecular ... levels of education. The report was prepared by ... of the AMP Training and Education Committee. "Our ... educating future medical laboratory scientists appropriately in order ...
(Date:4/22/2014)... is available in German . ... intracellular signaling molecules, but their mode of action is ... cellular function and behavior, while at high concentrations they ... DNA. To analyze how redox signaling unfolds in single ... technique has been developed jointly by the teams of ...
Breaking Medicine News(10 mins):Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 2Health News:New study finds 2.5 million basketball injuries to high school athletes in 6 seasons 3Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:AMP publishes curriculum recommendations for medical laboratory scientists 2Health News:Neuroimaging: Live from inside the cell 2
... FairWarning, Inc. a provider of healthcare privacy auditing ... titled Addressing Electronic Health Record Privacy ... The Webinar will feature John Wade, ... Robert Sullivan of PricewaterhouseCoopers, Healthcare Advisory ...
... Tour Shows Dramatic Impact of AIDS on Children, ... Funds for Social Causes, CINCINNATI, Feb. 13 ... Network (TPN), has partnered with World,Vision to produce ... a national tour designed to raise awareness about ...
... Monitoring Committee holds third meeting -, ... Life Sciences,Inc. (TSX: BNC), a research-based, technology-driven ... update on the progress,of its North American ... - trademarked Urocidin - in patients with ...
... Most Fertile ... Throughout Entire Month, PRINCETON, N.J., Feb. 13 Trying to predict ... provide,only a handful of chances to identify the two most fertile days ... most fertile,days: The new FIRST RESPONSE Daily Ovulation Test includes 20 testing,sticks ...
... for heart, pneumonia care, ST. PAUL, Minn., Feb. ... metro area in three key areas of a,national quality ... heart attack, heart failure and pneumonia care, according to,The ... "We,re very proud of the ongoing quality improvement work ...
... GARDENA, Calif., Feb. 13 Consumers today are ... away from,carbs, while other experts say that the ... we take in each day. The answers may ... oldest populations on earth, namely,Japan., Zojirushi ( ...
Cached Medicine News:Health News:FairWarning to Host Webinar Featuring HIMSS Chairman and Healthcare Executive from PricewaterhouseCoopers on Electronic Health Record Privacy and Compliance Challenges 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 2Health News:The Brand Experience Teams With World Vision to Launch 'Experience: AIDS' Multi-Media Exhibit 3Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 2Health News:Bioniche Provides Update on Refractory Bladder Cancer Trial with Urocidin(TM) 3Health News:New FIRST RESPONSE(R) Home Ovulation Test Takes the Guesswork Out of Conception 2Health News:Busting the Myth, One Bowl at a Time 2
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
Drugs of Abuse (DoA) Array is used for in-vitro diagnostic tests for the qualitative determination of the parent molecule and metabolites of drugs in human urine....
For use with catalog #0540....
Determination of FDP in Plasma by Latex Agglutination, 60 tests.Microlatex particles coated with mouse monoclonal anti-human FDP antibodies....
Medicine Products: